Teva Pharmaceutical Industries Ltd. $TEVA Stock Holdings Increased by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. lifted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 445,442 shares of the company’s stock after purchasing an additional 24,130 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Teva Pharmaceutical Industries were worth $14,056,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Oak Harvest Investment Services lifted its position in shares of Teva Pharmaceutical Industries by 154.8% in the fourth quarter. Oak Harvest Investment Services now owns 127,386 shares of the company’s stock worth $3,976,000 after purchasing an additional 77,386 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 10.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,495 shares of the company’s stock worth $265,000 after purchasing an additional 788 shares in the last quarter. PDS Planning Inc purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $236,000. United Advisor Group LLC raised its position in Teva Pharmaceutical Industries by 9.3% during the fourth quarter. United Advisor Group LLC now owns 17,600 shares of the company’s stock valued at $549,000 after acquiring an additional 1,500 shares in the last quarter. Finally, CWM LLC raised its position in Teva Pharmaceutical Industries by 39.2% during the fourth quarter. CWM LLC now owns 7,462 shares of the company’s stock valued at $233,000 after acquiring an additional 2,101 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Brian Savage sold 1,127 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $35,692.09. Following the sale, the insider owned 10,914 shares in the company, valued at approximately $345,646.38. This trade represents a 9.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Placid Jover sold 14,150 shares of the firm’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $448,130.50. Following the completion of the sale, the insider owned 6,774 shares in the company, valued at approximately $214,532.58. The trade was a 67.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 920,901 shares of company stock valued at $30,056,789 in the last 90 days. 0.54% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Trading Down 1.1%

Shares of Teva Pharmaceutical Industries stock opened at $32.04 on Tuesday. The company’s fifty day simple moving average is $31.47 and its 200-day simple moving average is $28.77. The company has a market cap of $36.84 billion, a price-to-earnings ratio of 26.70, a PEG ratio of 2.83 and a beta of 0.76. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a 1 year low of $13.04 and a 1 year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.62 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Jefferies Financial Group increased their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Piper Sandler reiterated an “overweight” rating and set a $41.00 price target (up from $40.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, March 4th. Truist Financial increased their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. The Goldman Sachs Group increased their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $38.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.